Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > REGULATORY
REGULATORY
- MOF Calls for Scrapping Price Maintenance Premium
April 21, 2017
- MHLW Cautions on Incidences of Multiple Vertebral Body Fractures after Discontinuation of Pralia Treatment
April 21, 2017
- MHLW Re-Cautions Use of Sleep/Anxiolytic/Epilepsy Agents Containing 44 APIs
April 19, 2017
- Optimal Use Guidelines Issued for Opdivo Use in RCC, Hodgkin’s Lymphoma
April 19, 2017
- New MHLW Panel Starts Discussions on Proper Drug Use Guidelines for Elderly; Final Report Expected by End of FY2018
April 19, 2017
- Amicus Takes Over GSK’s Orphan Status for Migalastat for Fabry’s Disease
April 18, 2017
- Review of 14-Day Prescription Limit Up for Chuikyo Discussion Again
April 18, 2017
- AMED to Launch Portal Site to Promote Use of Biobanks as Part of Effort to Support Genomic Medicine
April 18, 2017
- With Clinical Research Law Enacted, MHLW Eyes New Panel to Discuss Requirements for “Specified Clinical Research”: R&D Division Head
April 17, 2017
- Japan, South Korea to Hold 2nd Joint Regulation Symposium in May
April 17, 2017
- Clinical Research Law Promulgated
April 17, 2017
- MHLW Never Pressured Bayer on Announcement Timing for Xarelto Issue: Official
April 14, 2017
- Tokyo Govt Orders 2 “Cash-and-Carry” Dealers to Suspend Business
April 14, 2017
- Pricing Debate Timeline Updated, with 3 Hearing Sessions Now Planned
April 13, 2017
- CEFP Setting Sights on Drug Pricing, High-Cost Benefit System
April 13, 2017
- Opdivo’s Optimal Use Guidelines for RCC, Hodgkin’s Lymphoma to Take Effect on April 18
April 13, 2017
- Scrutinize Specific Process of Cost-Based Drug Pricing: Chuikyo Subcommittee
April 13, 2017
- Post-Launch Price Correction Floated for Imported Drugs 1st Approved in Japan: Chuikyo
April 13, 2017
- Average Price of Drugs Prescribed to Outpatients Rising Due to Increase in Number of High-Priced Drugs: CEFP Working Group
April 13, 2017
- Rebates, Allowances Come Up in CEFP Social Security Working Group’s Analysis of Current State of Wholesalers
April 13, 2017
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…